| Filed On | Filing |
|---|---|
| 04 Mar 2025 |
8-K: Other Events
On February 28, 2025, Syros Pharmaceuticals, Inc. (the “Company”) entered into a letter agreement with Oxford Finance LLC (“Oxford”), which provided for the repayment by the Company of all amounts owed under the loan and security agreeme... |
| 28 Feb 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Departure/Election of Directors or Officers; Compensation +1 more
CAMBRIDGE, Mass., February 28, 2025 – Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed with the voluntary delisting of its... |
| 08 Jan 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On January 6, 2025, Syros Pharmaceuticals, Inc. (“Syros”) received deficiency letters (the “Notices”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying Syros that: |
| 06 Dec 2024 |
8-K: Entry into a Material Definitive Agreement
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. |
| 18 Nov 2024 |
8-K: Termination of a Material Definitive Agreement; Triggering Events That Accelerate a Financial Obligation +2 more
On November 13, 2024, Syros Pharmaceuticals, Inc. (the “Company”) gave notice to QIAGEN Manchester Limited (“QIAGEN”) of its election to terminate the Master Collaboration Agreement dated March 7, 2022 (the “Agreement”) relating to the d... |
| 13 Nov 2024 |
8-K: Triggering Events That Accelerate a Financial Obligation; Other Events
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression |
| 05 Sep 2024 |
8-K: Regulation FD Disclosure
SOCIETY OF HEMATOLOGIC ONCOLOGY 12TH ANNUAL MEETING • September 4—7, 2024 • George R. Brown Convention Center • Houston, Texas SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult... |
| 12 Aug 2024 |
8-K: Other Events
CAMBRIDGE, Mass., August 12, 2024 – Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will disco... |
| 06 Jun 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 08 Jan 2024 |
8-K: Regulation FD Disclosure; Other Events
Advancing Novel Treatments for Hematologic Malignancies JP Morgan Conference January 2024 Exhibit 99.1 |
| 19 Dec 2023 |
8-K: Entry into a Material Definitive Agreement; Other Events
4,939,591 shares of common stock, par value $0.001 per share (the “Common Stock”) |
| 06 Dec 2023 |
8-K: Regulation FD Disclosure; Other Events
SELECT-AML-1: Initial Randomized Data Evaluating Tamibarotene in Newly Diagnosed AML Patients Ineligible for Standard Induction Therapy December 6, 2023 Exhibit 99.1 |
| 02 Oct 2023 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation
On October 2, 2023, Syros Pharmaceuticals, Inc. (the “Company”) announced a strategic realignment to prioritize key development and pre-launch activities to advance tamibarotene for the treatment of newly diagnosed higher-risk myelodyspl... |
| 11 Aug 2023 |
8-K: Termination of a Material Definitive Agreement
On August 9, 2023, Syros Pharmaceuticals, Inc. (the “Company”) received notice from Incyte Corporation (“Incyte”) that Incyte has elected to terminate the Target Discovery, Research Collaboration and Option Agreement dated January 8, 201... |
| 21 Jul 2023 |
8-K: Termination of a Material Definitive Agreement
On July 18, 2023, Syros Pharmaceuticals, Inc. (the “Company”) received notice from Pfizer, Inc. (“Pfizer”), as successor to Global Blood Therapeutics, Inc. (“GBT”) that Pfizer has elected to exercise its right to terminate the License an... |
| 02 Jun 2023 |
8-K: Submission of Matters to a Vote of Security Holders
The Company held its annual meeting of stockholders on June 1, 2023 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted in the following manner with respect to the following proposals: |
| 25 May 2023 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.1 Advancing Novel Treatments for Hematologic Malignancies May 2023 |
| 10 Mar 2023 |
8-K: Regulation FD Disclosure
Syros Pharmaceuticals, Inc. (the “Company”) discloses that, as of March 10, 2023, it has two deposit accounts at Silicon Valley Bank. One of these accounts has a balance of less than $250,000, and the other has a balance of approximately... |
| 09 Jan 2023 |
8-K: Regulation FD Disclosure; Other Events
Advancing Novel Treatments for Hematologic Malignancies January 2023 Exhibit 99.1 |
| 12 Dec 2022 |
8-K: Regulation FD Disclosure; Other Events
An Expression Makes a World of Difference December 2022 Exhibit 99.1 |
Loading...